Author: Vena, Daniel ; Sands, Scott ; White, David P. ; Hess, Lauren ; Taranto‐Montemurro, Luigi ; Azarbarzin, Ali ; Calianese, Nicole ; Kim, Sang‐Wook ; Wellman, Andrew

ABSTRACTBackground and objectiveAnimal studies indicate that alpha‐1 adrenergic receptor agonists and antimuscarinic agents improve genioglossus muscle activity during sleep and may be candidates for the pharmacological treatment of OSA. On the other hand, noradrenergic stimulants may be wake‐promoting or cause insomnia symptoms if taken before bedtime, and the addition of a medication with sedative properties, such as an antihistaminic, may reduce these side effects. In this study, we aimed to determine the effects of the combination of an alpha‐1 adrenergic agonist (pseudoephedrine) and an antihistaminic‐antimuscarinic (diphenhydramine) on OSA severity (AHI), genioglossus responsiveness and other endotypic traits (Vpassive, muscle compensation, LG and arousal threshold).MethodsTen OSA patients performed a randomized, placebo‐controlled, double‐blind, crossover trial comparing one night of pseudoephedrine 120 mg plus diphenhydramine 50 mg (DAW1033D) to placebo administered prior to sleep. The AHI, genioglossus muscle responsiveness to negative oesophageal pressure and the endotypic traits were measured via PSG.ResultsThe participants' median (interquartile range) age was 50 (46–53) years and body mass index (BMI) was 34.3 (30.6–39.2) kg/m2. The drug combination had no effect on AHI (21.6 (9.1–49.8) on placebo vs 37.9 (5.1–55.4) events/h on DAW1033D, P > 0.5) or genioglossus responsiveness (6.0 (2.6–9.2) on placebo vs 4.0 (3.5–7.3) %/cm H2O). Amongst the phenotypic traits, only Vpassive was improved by 29 (3–55) % eupnoea, P = 0.03 (mean (95% CI)).ConclusionThe combination of pseudoephedrine and diphenhydramine did not improve OSA severity or genioglossus responsiveness but induced a small improvement in upper airway collapsibility, possibly due to the decongestant effect of the medications. The results of this study do not support the use of these medications for OSA treatment.

100 Deals associated with DAW1033D

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Sleep Apnea, Obstructive	Phase 2	-	The Brigham & Women's Hospital, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

DAW1033D

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation